These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29535503)

  • 1. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.
    Xia T; Zhu S; Wen Y; Gao S; Li M; Tao X; Zhang F; Chen W
    Drug Des Devel Ther; 2018; 12():417-428. PubMed ID: 29535503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
    Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
    Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
    Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.
    Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ;
    Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation.
    Kim H; Han A; Ahn S; Min SK; Ha J; Min S
    Sci Rep; 2023 Oct; 13(1):16502. PubMed ID: 37783764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney donor age of 50 years or above is a risk factor for calcineurin inhibitor-induced nephrotoxicity.
    Takada Y; Tanabe T; Sasaki H; Tsujimoto T; Hotta K; Okada K; Shiono Y; Minami K; Tanaka H; Harada H
    Clin Transplant; 2024 Jan; 38(1):e15196. PubMed ID: 37975424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
    Bentata Y
    Artif Organs; 2020 Feb; 44(2):140-152. PubMed ID: 31386765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitors and nephrotoxicity in children.
    Liu F; Mao JH
    World J Pediatr; 2018 Apr; 14(2):121-126. PubMed ID: 29532435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.
    Camilleri B; Bridson JM; Halawa A
    Exp Clin Transplant; 2016 Oct; 14(5):471-483. PubMed ID: 27213490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
    Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
    Hesselink DA; Bouamar R; van Gelder T
    Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of calcineurin inhibitors for kidney-transplant patients.
    Malvezzi P; Rostaing L
    Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
    Zhang W; Fung J
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin Inhibitors Nephrotoxicity Prevention Strategies With Stress on Belatacept-Based Rescue Immunotherapy: A Review of the Current Evidence.
    El Hennawy HM; Faifi ASA; El Nazer W; Mahedy A; Kamal A; Al Faifi IS; Abdulmalik H; Safar O; Zaitoun MF; Fahmy AE
    Transplant Proc; 2021 Jun; 53(5):1532-1540. PubMed ID: 34020797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis.
    Cornu C; Dufays C; Gaillard S; Gueyffier F; Redonnet M; Sebbag L; Roussoulières A; Gleissner CA; Groetzner J; Lehmkuhl HB; Potena L; Gullestad L; Cantarovich M; Boissonnat P
    Br J Clin Pharmacol; 2014 Jul; 78(1):24-32. PubMed ID: 24251918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.